The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome

Selma MV, González-Sarrías A, Salas-Salvadó J, Andrés-Lacueva C, Alasalvar C, Orem A, Tomás-Barberán FA, Espín JC · Clinical Nutrition

Confirms the metabotypes in people rather than in principle, and finds the distribution shifts with metabolic status — the metabotype associated with worse cardiometabolic biomarkers becomes more common as weight and metabolic syndrome increase.

Population

Adults across normal weight, overweight-obesity and metabolic syndrome, given pomegranate or walnut ellagitannins

Intervention

Dietary ellagitannins

Comparator

Comparison across metabotype and body-weight strata

Limitations

Cardiometabolic biomarkers, not joints, and metabotype is not randomly assigned — it travels with diet, weight and the rest of the microbiome.